Skip to main content
. Author manuscript; available in PMC: 2014 Aug 6.
Published in final edited form as: Clin Cancer Res. 2012 Dec 17;19(3):517–523. doi: 10.1158/1078-0432.CCR-12-1452

Figure 1. Molecular sub-classification of prostate cancer.

Figure 1

Disease initiation occurs through activation of androgen signaling, complex rearrangements, or other proposed mechanisms, leading to prostate tumors wide clinical heterogeneity and distinct molecular subtypes. Disease progression and resistance to therapy leads to acquisition of new and potentially overlapping molecular alterations.